In cardio-oncology, abnormal natriuretic peptides are associated with an increased risk of cardiac dysfunction, major adverse cardiac events, and cardiac death.7,8,9 Current societal statements suggest that circulating biomarkers such as N-terminal pro–B-type natriuretic peptide (NT-proBNP) are to be used in the risk stratification of patients treated with cardiotoxic cancer therapies,10,11 although the evidence to support this, and how exactly measures should guide therapy, are significant knowledge gaps. Here, NPPB is linked to cancer.